SmithKline Beecham
GSKs newest neuro pact is with ABL Bio, a Sanofi-partnered South Korean biotech
Abetalipoproteinemia, SmithKline Beecham, Bio, Grabody-B, Neurodegenerative Disorders, Blood – brain barrier anatomy, IGF1R gene
FDA Approves Blujepa: First New Oral Antibiotic for Uncomplicated UTIs in Nearly 30 Years
Gepotidacin, Blujepa, GSK, uncomplicated urinary tract infections (uUTIs), FDA approval, first-in-class antibiotic
GSK Launches Groundbreaking Study on Shingrix and Dementia Risk Reduction
GSK, Shingrix, dementia, UK Dementia Research Institute, Health Data Research UK, NHS data, real-world experiment
GSK’s Penmenvy Approved: New 5-in-1 Meningococcal Vaccine Enters U.S. Market
Penmenvy, GSK, meningococcal vaccine, FDA approval, 5-in-1 vaccine, MenABCWY, invasive meningococcal disease (IMD)
GSK’s Penmenvy Gains FDA Approval, Joining Pfizer in 5-in-1 Meningococcal Vaccine Market
Penmenvy, GSK, FDA approval, meningococcal vaccine, 5-in-1 vaccine, Pfizer, Penbraya, invasive meningococcal disease (IMD), adolescents and young adults
Battle for HIV PrEP Market: Gilead’s Twice-Yearly Injection Challenges GSK’s Apretude
HIV prevention, PrEP, lenacapavir, Apretude, long-acting injectables, Gilead Sciences, GSK, ViiV Healthcare
Chinese Vaccine Biotech Ab&B Files for IPO, Drawing Attention from GSK, Merck, and Pfizer
Ab&B Bio-Tech, IPO, Chinese vaccine biotech, GSK, Merck, Pfizer, biotechnology, pharmaceutical industry
GSK’s Strategic Approach to Deal-Making and Expansion Beyond Obesity with GLP-1s
GSK, GLP-1s, Obesity, Deal-making, Strategic expansion, Pharmaceutical innovation, R&D strategy
Pharmaceutical CEOs Emphasize Transparency to Counter Anti-Vaccine Sentiment in the US
Anti-vaccine movement, Transparency, GSK, Sanofi, Vaccine hesitancy, Public health
GSK Advances Liver Disease Research and Biotech CEO Sisterhood Grows Influence
GSK, liver disease, Biotech CEO Sisterhood, JPM25, pharmaceutical industry, women in biotech